LeMaitre Vascular director reports share gains from dividend rights

A LeMaitre Vascular Inc. director reported stock transactions tied to dividend equivalent rights that vested on 12/12/2025.

Rhea-AI Filing Summary

A LeMaitre Vascular Inc. director reported stock transactions tied to dividend equivalent rights that vested on 12/12/2025. The director acquired 5 shares of common stock in each of two transactions at a price of $0 per share, reflecting the release of dividend equivalent rights on a one-for-one basis into common stock.

Following these transactions, the director beneficially owned 62,350 shares of LeMaitre Vascular common stock directly. The derivative positions shown were dividend equivalent rights linked to restricted stock unit and performance stock unit awards granted on 12/12/2022, each right being the economic equivalent of one share. After vesting, the number of these derivative rights was reduced to zero, with any fractional shares settled in cash.

Insider Trade Summary

10 shares exercised/converted

Exercise 4 txns

Insider O'Connor John James

Role Director

Type	Security	Shares	Price	Value
Exercise	Dividend Equivalent Rights	5	$0.00	$0.00
Exercise	Dividend Equivalent Rights	5	$0.00	$0.00
Exercise	Common Stock	5	$0.00	$0.00
Exercise	Common Stock	5	$0.00	$0.00

Holdings After Transaction: Dividend Equivalent Rights — 0 contracts (Direct); Common Stock — 62,350 shares (Direct)

Footnotes (4)

1. F1. Represents shares acquired upon release of dividend equivalent rights, as reported in Table II, on a one-for-one basis.
2. F2. These dividend equivalent rights were released in connection with the vesting of a restricted stock unit award granted on 12/12/2022. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
3. F3. Fractional shares (if any) were settled in cash on each vesting date, resulting in a final balance of zero.
4. F4. These dividend equivalent rights were released in connection with the vesting of a performance stock unit award granted on 12/12/2022. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did LMAT report in this Form 4?

A director of LeMaitre Vascular Inc. (LMAT) reported acquiring common stock on 12/12/2025 when dividend equivalent rights vested and converted into shares at $0 per share.

How many LMAT shares were acquired and at what price?

The director acquired 5 shares of LeMaitre Vascular common stock in each of two transactions, with each share acquired at a price of $0 upon release of dividend equivalent rights.

How many LMAT shares does the director own after these transactions?

After the reported transactions, the director beneficially owned 62,350 shares of LeMaitre Vascular common stock in direct ownership.

What are the dividend equivalent rights mentioned for LMAT?

The filing describes dividend equivalent rights where each right is the economic equivalent of one share of LeMaitre Vascular common stock and converts into shares when related awards vest.

Which LMAT equity awards were tied to these dividend equivalent rights?

The dividend equivalent rights were released in connection with the vesting of a restricted stock unit award and a performance stock unit award, both granted on 12/12/2022.

What happened to the LMAT dividend equivalent rights balance after vesting?

After the vesting transactions on 12/12/2025, the number of dividend equivalent rights was reduced to zero, with any fractional shares settled in cash.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/15/2025 - 06:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Connor John James

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		M		5(1)	A	$0(1)	62,345	D
Common Stock	12/12/2025		M		5(1)	A	$0(1)	62,350	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Dividend Equivalent Rights	(2)	12/12/2025		M			5(2)	(2)	(2)	Common Stock	5	$0	0(3)	D
Dividend Equivalent Rights	(4)	12/12/2025		M			5(4)	(4)	(4)	Common Stock	5	$0	0(3)	D

Explanation of Responses:

1. Represents shares acquired upon release of dividend equivalent rights, as reported in Table II, on a one-for-one basis.

2. These dividend equivalent rights were released in connection with the vesting of a restricted stock unit award granted on 12/12/2022. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

3. Fractional shares (if any) were settled in cash on each vesting date, resulting in a final balance of zero.

4. These dividend equivalent rights were released in connection with the vesting of a performance stock unit award granted on 12/12/2022. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

	/s/ Laurie A. Churchill, Attorney-in-fact	12/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.